Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Theralase Technologies ( (TSE:TLT) ).
Theralase Technologies Inc. has announced a brokered private placement offering to raise between C$4.5 million and C$5.5 million, with Research Capital Corporation as the sole agent. The funds will primarily support a Phase II clinical study for non-muscle invasive bladder cancer and other strategic initiatives, potentially enhancing Theralase’s market position in cancer treatment.
The most recent analyst rating on (TSE:TLT) stock is a Buy with a C$0.70 price target. To see the full list of analyst forecasts on Theralase Technologies stock, see the TSE:TLT Stock Forecast page.
Spark’s Take on TSE:TLT Stock
According to Spark, TipRanks’ AI Analyst, TSE:TLT is a Underperform.
Theralase Technologies’ overall stock score is primarily impacted by its weak financial performance and valuation metrics. The bearish technical indicators further contribute to the low score, reflecting the company’s ongoing challenges and lack of profitability.
To see Spark’s full report on TSE:TLT stock, click here.
More about Theralase Technologies
Theralase Technologies Inc. is a clinical stage pharmaceutical company focused on the development of therapeutics activated by light, radiation, sound, and drugs for treating cancer, bacteria, and viruses.
Average Trading Volume: 112,232
Technical Sentiment Signal: Sell
Current Market Cap: C$47.56M
For detailed information about TLT stock, go to TipRanks’ Stock Analysis page.